Inyesprin (D,l-Lysine Acetylsalicylate)

The compound reversibly blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which stops the formation of prostaglandins and thromboxanes. This inhibition reduces pain signals, lowers body temperature, diminishes inflammatory swelling, and decreases platelet clumping.

The appropriate dose of Inyesprin is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety of D,L-lysine acetylsalicylate in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Inyesprin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inyesprin delivers the active salicylate as a lysine salt, allowing rapid intramuscular or intravenous administration, which can be advantageous in acute settings. Compared with oral NSAIDs, it provides faster onset but shares a similar safety profile regarding gastrointestinal and renal effects.

Inyesprin should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme temperatures to maintain its stability.

Inyesprin is supplied as a sterile solution for injection. It can be given either intramuscularly or intravenously by a qualified healthcare professional, following aseptic technique and the dosage prescribed by the treating physician.

The most serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, renal impairment, and significant platelet dysfunction leading to abnormal bleeding. Patients should be monitored closely for these events.

Inyesprin should be avoided in individuals with known hypersensitivity to salicylates, active gastrointestinal ulceration, recent major surgery, severe renal or hepatic impairment, and in patients receiving anticoagulant therapy unless closely supervised by a physician.